Last reviewed 2026-04-20 · How we verify

Alphanon (CAMPHOR)

Alphanon, a camphor-based topical analgesic, is currently marketed for muscle and joint pain relief, positioning it in a competitive landscape with several same-class drugs. Its key strength lies in its immediate pain-relieving mechanism, which provides a non-systemic option for patients seeking localized treatment. The primary risk to Alphanon is the key composition patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Approved indications

• Muscle and joint pain relief

Common side effects

No common side effects on file.

Key clinical trials

• Effect of Chinese Herbal Medicine Nasal Irrigation on the Postoperative Care of Chronic Rhinosinusitis (PHASE2)
• To Check Dermatological Safety of Test Products by 24 Hours Patch Testing (NA)
• imprOving Adherence to Pulmonary artErial hyperteNsion Treatment With teLemedicIne and patieNt guidaNce (NA)
• A Single Group Study to Evaluate the Effects of a Topical Product on Cramps Associated With the Menstrual Cycle (NA)
• Transient Receptor Potential Channels (EARLY_PHASE1)
• Changyanning Tablet for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) (PHASE2,PHASE3)
• Safety and Efficacy of Compound Methyl Salicylate Liniment for Topical Pain: a Multicenter Real-World Study in China
• The Effect on Thirst, Nausea-Vomiting and Comfort Levels of Menthol Lozenge Applied After Extubation (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Alphanon CI brief — competitive landscape report
• Alphanon updates RSS · CI watch RSS